🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs
987

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 987 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Page 3 of 21

  1. Fasinumab

    Regeneron UK Limited

    Osteoarthritis of the Knee or Hip

    phase 3 small molecule completed

    1 trial

  2. Fasinumab

    Regeneron UK Limited

    Osteoarthritis, Knee

    phase 3 small molecule completed

    4 trials

  3. Filgotinib

    Lakefront Biotherapeutics NV

    Psoriatic Arthritis

    phase 3 small molecule terminated

    4 trials

  4. Filgotinib

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 3 small molecule completed

    2 trials

  5. Filgotinib

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  6. Filgotinib

    Alfasigma S.p.A.

    Axial Spondyloarthritis

    phase 3 small molecule active

    1 trial

  7. Film-Coated Tablet without Deucravacitinib, Film-Coated Tablet without JNJ-77242113, DEUCRAVACITINIB, JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  8. Film-Coated Tablet without JNJ-77242113, JNJ-77242113

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  9. Fostamatinib disodium

    RIGEL PHARMACEUTICALS INC

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    2 trials

  10. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  11. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    Juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  12. GSK1605786A

    GlaxoSmithKline

    Crohn's Disease

    phase 3 small molecule terminated

    2 trials

  13. GSK3196165 (Otilimab)

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 3 mab completed

    1 trial

  14. GW406381

    GlaxoSmithKline

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  15. Gazyva Placebo, Gazyvaro 1,000 mg concentrate for solution for infusion.

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  16. Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  17. Golimumab 1 mg per kg

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule terminated

    1 trial

  18. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  19. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  20. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, STELARA 90 mg solution for injection in pre-filled syringe, Placebo for Ustekimumab, Placebo for Guselkumab, STELARA 130 mg concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  21. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  22. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Type Psoriasis

    phase 3 small molecule active

    1 trial

  23. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  24. Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  25. Guselkumab Dose 1

    Janssen Cilag International NV

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  26. Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo

    Janssen-Cilag International N.V.

    Moderate to Severly Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  27. Guselkumab, Placebo 0.5ml equivalent, Guselkumab- Solution for infusion- 10 mg/ml, Placebo 2.0ml equivalent, Guselkumab, Placebo 1.0ml equivalent, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  28. Guselkumab- Solution for infusion- 10 mg/ml, Placebo to Guselkumab, Placebo to Guselkumab solution for injection in pre-filled syringe -100 mg/ml, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Placebo to Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Fistulizing perianal Crohn's Disease

    phase 3 small molecule active

    1 trial

  29. HYDROXYCHLOROQUINE, METHOTREXATE, Remsima 120 mg solution for injection in pre-filled pen, METHOTREXATE, IBUPROFEN, Placebo (To evaluate the efficacy and safety of CT-P13, and mainatain blindness during the study, Placebo will be administered.), PARACETAMOL, FOLIC ACID, HYDROCORTISONE

    Celltrion Healthcare Australia Pty Ltd

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  30. Humira 20 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Humira 80 mg solution for injection in pre-filled syringe, Humira 40 mg/0.8 ml solution for injection

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  31. Humira 40 mg solution for injection in pre-filled syringe, Abatacept

    Bristol-Myers Squibb Australia Pty Ltd

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  32. Humira 40 mg solution for injection in pre-filled syringe, ORENCIA 50 mg solution for injection in pre-filled syringe, Tyenne 162mg/0.9ml solution for injection in pre-filled syringe, Humira 20 mg solution for injection in pre-filled syringe, XELJANZ 1 mg/mL oral solution, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, XELJANZ 5 mg film-coated tablets, ORENCIA 87.5 mg solution

    The George Institute

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  33. Humira 40 mg solution for injection in pre-filled syringe, Risankizumab, Humira 20 mg solution for injection in pre-filled syringe, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Juvenile Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  34. INEBILIZUMAB, 10 mL (nominal) solution containing 10 mM histidine/histidine hydrochloride, 75 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.02% (w/v) polysorbate 80, pH 6.0

    Elan Pharma International

    Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).

    phase 3 small molecule active

    1 trial

  35. IV Tulisokibart

    Merck KGaA, Darmstadt, Germany

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  36. IV Tulisokibart

    Merck KGaA, Darmstadt, Germany

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  37. Icotrokinra

    Janssen Cilag International NV

    Crohn Disease

    phase 3 small molecule active

    1 trial

  38. Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  39. Ilumetri 100 mg solution for injection in pre-filled syringe, Tildrakizumab placebo solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  40. Ilumetri 100 mg solution for injection in pre-filled syringe, tildrakizumab placebo solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  41. Infliximab + methotrexate (IFX + MTX)

    Universal Integrated

    Arthritis, Psoriatic

    phase 3 small molecule completed

    1 trial

  42. Infliximab Increased Frequency

    Universal Integrated

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  43. Intravenous Immunoglobulin

    Option Therapeutics

    Autoimmune Epilepsy

    phase 3 small molecule terminated

    1 trial

  44. Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Warm Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    1 trial

  45. JNJ-77242113

    Janssen Cilag International NV

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  46. JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  47. JNJ-77242113, Film-Coated Tablet without JNJ-77242113, Film-Coated Tablet without Deucravacitinib, DEUCRAVACITINIB

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  48. JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

987 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.